Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosmanogepix for C. auris Candidemia/Invasive Candidiasis
NCT04148287Phase 2Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Dec 2019
- Primary completion
- Nov 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fosmanogepix in candidemia, invasive candidiasis, sponsored by Basilea Pharmaceutica. Started Dec 2019; status: completed.
02
Drugs
fosmanogepix
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT04148287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148287.